UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...
There have been great advances in the field of generalised myasthenia gravis (gMG) in recent years ... and John Vissing, Copenhagen Neuromuscular Centre, Rigshospitalet, Denmark, share their expert ...
1 Department of Neurology, Wuhan No. 1 Hospital, Wuhan, China 2 The First Clinical Medical Institute, Hubei University of Chinese Medicine, Wuhan, China Introduction/Aims: Myasthenia Gravis (MG) is a ...
Large-scale studies are needed to confirm these findings. Myasthenia gravis (MG) is an autoimmune disease affecting the neuromuscular junction; it is primarily caused by the production of ...
Efgartigimod efficacy and safety in refractory myasthenia gravis: UK’s first real-world experience
Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction that causes fatigable neuromuscular weakness. 85% of patients have antibodies against the acetylcholine receptor (AChR) ...
Medications for myasthenia gravis (MG ... Eculizumab helps prevent neuromuscular junction damage. You’ll receive it weekly for 4 weeks, followed by every 2 weeks, and is approved for people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback